leadf
logo-loader
viewBioSig Technologies, Inc.

BioSig Technologies enrolling patients in its Phase 2 clinical trial to treat coronavirus in major US hotspots

BioSig Technologies Inc (NASDAQ:BSGM) CEO Kenneth Londoner tells Proactive the Connecticut-based biotech is enrolling patients for its Phase 2 trial of merimepodib, its drug candidate for the treatment of the coronavirus.

Londoner says BioSig, along with its subsidiary ViralClear Pharmaceuticals Inc, is enrolling patients at trial sites in Austin, Texas; Rochester, Minnesota; Jacksonville, Florida; and Scottsdale, Arizona, expecting to report results later this summer.

Quick facts: BioSig Technologies, Inc.

Price: 4.5 USD

NASDAQ:BSGM
Market: NASDAQ
Market Cap: $138.24 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of BioSig Technologies, Inc. named herein, including the promotion by the Company of BioSig Technologies, Inc. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

BioSig Technologies taps seasoned life sciences exec Brenda Castrodad to...

BioSig Technologies, Inc. (NASDAQ:BSGM) Head of Human Resources Brenda Castrodad tells Proactive she's excited to begin work at the Westport, Connecticut-based medical technology company. Castrodad tells Proactive about her experience in leading organizational development in start-ups and...

1 week, 5 days ago

2 min read